Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: Results from IMPACT 2 trial

被引：0
|
作者：
Van der Heljde, D
Kavanaugh, A
Beutler, A
Guzzo, C
Zhou, B
Dooley, L
Antonl, CE
Krueger, GG
Gladman, D
机构：
[1] Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands
[2] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
[3] Centocor Inc, Clin Res & Dev, Malvern, PA 19355 USA
[4] Univ Erlangen Nurnberg, Dept Med 3, Erlangen, Germany
[5] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT USA
[6] Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [21] Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
    Kavanaugh, A.
    Krueger, G. G.
    Beutler, A.
    Guzzo, C.
    Zhou, B.
    Dooley, L. T.
    Mease, P. J.
    Gladman, D. D.
    de Vlam, K.
    Geusens, P. P.
    Birbara, C.
    Halter, D. G.
    Antoni, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (04) : 498 - 505
  • [22] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Antoni, CE
    Kavanagh, A
    Kirkham, B
    Tutuncu, Z
    Burmester, GR
    Schneider, U
    Furst, DE
    Molitor, J
    Keystone, E
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, DJ
    Weisman, MH
    Kalden, JR
    Smolen, J
    ARTHRITIS AND RHEUMATISM, 2005, 52 (04): : 1227 - 1236
  • [23] Efficacy of infliximab in psoriatic arthritis-related dactylitis and enthesopathy: Results from the impact 2 trial
    Kavanaugh, A
    Mease, P
    Beutler, A
    Antoni, C
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P183 - P183
  • [24] Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    Antoni, Christian E.
    Kavanaugh, Arthur
    van der Heijde, Desiree
    Beutler, Anna
    Keenan, Gregory
    Zhou, Bie
    Kirkham, Bruce
    Tutuncu, Zuhre
    Burmester, Gerd R.
    Schneider, Udo
    Furst, Daniel E.
    Molitor, Jerry
    Keystone, Edward
    Gladman, Dafna D.
    Manger, Bernhard
    Wassenberg, Siegfried
    Weier, Ralf
    Wallace, Daniel J.
    Weisman, Michael H.
    Kalden, Joachim R.
    Smolen, Josef S.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (05) : 869 - 876
  • [25] Infliximab treatment dissociates the effect of CRP on radiographic progression in patients with psoriatic arthritis.
    Kavanaugh, A.
    Antoni, C. E.
    Krueger, G. G.
    van der Heijde, D. M.
    Beutler, A.
    Zhou, B.
    Guzzo, C.
    Han, C.
    Bala, M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4045 - 4045
  • [26] 2-year data: Infliximab maintains clinical response in psoriatic arthritis patients-data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, ZN
    Burmester, G
    Schneider, U
    Furst, DE
    Moliter, J
    Keystone, EC
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, M
    Kalden, JR
    Smolen, JS
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S209 - S209
  • [27] The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, C
    Kavanaugh, A
    Kirkham, B
    Burmester, G
    Manger, B
    Schneider, U
    Tutuncu, Z
    Ebner, W
    Wassenberg, S
    Furst, D
    Molitor, J
    Keystone, E
    Gladman, D
    Weisman, M
    Wallace, D
    Kalden, J
    Smolen, J
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S265 - S266
  • [28] Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
    van der Heijde, Desiree
    Okada, Masato
    Lee, Chin H.
    Shuler, Catherine
    Rathmann, Suchitrita
    Lin, Chen-Yen
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [29] RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH IXEKIZUMAB OVER 52 WEEKS
    van der Heijde, D.
    Okada, M.
    Lee, C.
    Shuler, C. L.
    Rathmann, S.
    Lin, C. -Y.
    Mease, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 144 - 145
  • [30] Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
    van der Heijde, Desiree
    Chandran, Vinod
    Fleischmann, Roy
    Benichou, Olivier
    Rathmann, Suchitrita
    Shuler, Catherine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 846
12345